Clinical Trial Update: Ipilimumab 12-month Intensive Pharmacovigilance Protocol

View source ↗

Summary

This document reports the completion of a 12-month intensive pharmacovigilance protocol for ipilimumab in melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Status: COMPLETED